Abstract. Low reactive level laser therapy (LLLT) has been used in many clinical studies in the past. However, the acting mechanisms of LLLT have not yet been satisfac torily clarified. As has been reported in some journals, LLLT may induce pain relief through the function of the opioids nerve and the activating of macrophages and T-lymphocytes in both vivo and vitro. We thought that the results reported in various journals might indicate the possibility of using LLLT to moderate the immune system through the skin. We studied the effect of LLLT (830nm, 60mW) in tumor bearing hosts using a glioma implanted in mice as compaired with the effect of other therapies.
Materials and Methods
Animal and tumor model C57 Black Mice, male, aged 3 weeks were used in this study. Glioma cell line (203 GL) induced by meth ylcolanthrene in mice was used. The implanted glioma was created by removing a small section (8mm3) of a tumor from one mouse and injecting it subcutaneously into the dorsal area of another. Two different models were used. In the first model, therapies were applied post the first day of tumor implantation. In the second, therapies were applied post the fourteenth day of tumor implantation. Estimation of the effect of therapies: The effectiveness of therapies was estimated by both the incidence and the growth volume of the implanted tumor over a 32 day period according to the following formula:
Results
Results of each therapy in the model of post the first day of glioma implantation (Fig  2) .
Results of each therapy in the model of post the fourteenth day of glioma implantation 
Discussion
The relation between LLLT and immunological res ponse has been considered in several journals.2-5 Dima et al5 report that photodynamic therapy increased the activity of lumphocytes in non-irradiated regions. In our study the effects of both direct and indirect LLLT inhibited the growth after glioma implantation, indicating that it might induce anti-tumoral effects via skin tissue. These results allow us to speculrate that LLLT might contribute to a photoimmunological system. However, when applied to the model fourteenth day post glioma implantation, indirect LLLT contributed to the growth of the tumor. These results raise the question as to why the same therapy should limit the tumor growth when applied post first day of glioma implantation, and yet produce adverse results when applied post fourteenth day of glioma implantation. The active role of the LLLT (830nm) in vivo model might depend on the biological interaction including the immune system between the tumor bearing host and the tumor. Further experiment ation will be necessary to investigate the results from the viewpoint of the immunological interaction. However, our results are intriguing when compared with the effect of ultraviolet irradiation on the development of the cancer growth in the primary host.6
